宁波均胜电子（600699）有限公司(简称：均胜电子)(600699.SH)将于10月20日启动港股上市前PDIE(Pre-Deal Investor Education)，目标交易规模约4至5亿美元。据港交所披露，均胜电子8月7日二次递表港交所主板，中金公 司（601995）和瑞银集团为其联席保荐人。目前均胜电子港股IPO已获中国证监会备案。 招股书显示，均胜电子是智能汽车科技解决方案提供商，提供汽车零部件行业关键领域(主要为汽车电子和汽车 安全)的先进产品和解决方案。公司业务专注于汽车零部件的研发、制造和销售，于2024年全球汽车零部件行业 中排名第四十一，根据弗若斯特沙利文的资料，按收入计，公司是中国和全球第二大汽车被动安全产品供货商。 均胜电子已搭建高度全球化平台。截至2025年4月30日，公司在全球设有超过25个研发中心和超过60个生产基 地，覆盖亚洲、欧洲和北美等主要汽车市场。公司的全球化战略已证实卓有成效，其中境外销售额占2024年总收 入的74.7%。此外，公司从2021年至2024年连续四年在中国跨国公司100大及跨国指数中排名第一。 公司募资金额拟用于通过投资于新一代汽车智能解决方案和前沿 ...

9月30日，中国证监会国际合作司发布《关于宁波均胜电子（600699）股份有限公司境外发行上市备案通知书》。均胜电子(600699.SH)拟发行不超过 283,239,000股境外上市普通股并在香港联合交易所上市。 | 索 引 号 | | bm56000001/2025-00011543 | ਲੇ | | 结果公 | | --- | --- | --- | --- | --- | --- | | 发布机构 | | | 发文日期 | | 2025年 | | ਲ | 称 | 关于宁波均胜电子股份有限公司境外发行上市备案通知书 | | | | | 文 | 号 | 国合函〔2025〕 1698 号 | 主题词 | | | 招股书显示，均胜电子是智能汽车科技解决方案提供商，提供汽车零部件行业关键领域(主要为汽车电子和汽车安全)的先进产品和解决方案。公司业务专注 于汽车零部件的研发、制造和销售，于2024年全球汽车零部件行业中排名第四十一，根据弗若斯特沙利文的资料，按收入计，公司是中国和全球第二大汽车 被动安全产品供货商。 ...

Group 1: IPO Overview - This week, three companies submitted their IPO applications: Junsheng Electronics, Haijing Zhiyuan, and Haixi New Drug [2][3] - Next week, Yinnuo Pharmaceutical-B (weight loss drug) and Zhonghui Biotechnology-B (vaccine) are expected to be listed, presenting potential investment opportunities [1][2] Group 2: Company Profiles - **Junsheng Electronics**: A leading provider of smart automotive technology solutions, ranked 41st globally in the automotive parts industry in 2024. The company is the second-largest supplier of passive safety products in China and globally, with 74.7% of its revenue from overseas sales in 2024 [3] - **Haijing Zhiyuan Technology**: A leading Chinese multispectral AI technology company, with revenues of approximately CNY 224.7 million, CNY 117.1 million, and CNY 522.6 million for the fiscal years 2022, 2023, and 2024 respectively, reflecting a compound annual growth rate of about 52.5% [4] - **Haixi New Drug**: A commercial-stage pharmaceutical company with a diverse product portfolio in the fastest-growing therapeutic areas in China. The company focuses on innovative drugs with significant global market potential, including a potential first-in-class oncology drug [5][6] Group 3: Upcoming Listings - **Yinnuo Pharmaceutical-B**: The first in Asia and third globally to advance a novel GLP-1 receptor agonist to the registration approval stage, with an expected IPO fundraising of HKD 683 million at a price of HKD 18.68 per share [9][10] - **Zhonghui Biotechnology-B**: A vaccine company focused on innovative vaccines and traditional vaccines using new technologies, with an expected IPO fundraising of HKD 518 million at a price range of HKD 12.90 to HKD 15.50 per share [9][10]